Avalo Therapeutics Inc AVTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $13.24
- Day Range
- $11.99–13.23
- 52-Week Range
- $11.99–24.27
- Bid/Ask
- $11.60 / $12.25
- Shares Outstanding
- 53.63M
- Market Cap
- $644.10M
- Volume/Avg
- 2M / 927,417
Key Statistics
- Price/Earnings (Normalized)
- 2.77
- Price/Sales
- 4,892.06
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 33
- Website
- https://www.avalotx.com
Valuation
|
Metric
|
AVTX
|
|---|---|
Price/Earnings (Normalized) | 2.77 |
Price/Book Value | 1.42 |
Price/Sales | 4,892.06 |
Price/Cash Flow | — |
Price/Earnings
AVTX
Financial Strength
|
Metric
|
AVTX
|
|---|---|
Quick Ratio | 18.94 |
Current Ratio | 19.31 |
Interest Coverage | — |
Quick Ratio
AVTX
Profitability
|
Metric
|
AVTX
|
|---|---|
Return on Assets (Normalized) | −39.54% |
Return on Equity (Normalized) | −47.62% |
Return on Invested Capital (Normalized) | −50.30% |
Return on Assets
AVTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|FR!bLL | LOCK|@%@% | $123B | |||
| Moderna Inc
MRNA
| LOCK|v>t^!$ | LOCK|QZz | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|K@<Qf!K | LOCK|$&>n | $78B | |||
| argenx SE ADR
ARGX
| LOCK|CgHTyl | LOCK|HJ | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|XNY!^x& | LOCK|>K | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|rmnL>< | LOCK|#$Xh? | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>&Z?%^C | LOCK|jvx@ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|^Jn<dG> | LOCK|%> | $22B | |||
| Incyte Corp
INCY
| LOCK|n<S$ykX | LOCK|Dg? | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|TbyGS< | LOCK|?bd | $14B |
United States